The Manufacturers Life Insurance Company Grows Stock Position in Alumis Inc. $ALMS

Posted by Brian Himes on Aug 8th, 2026

The Manufacturers Life Insurance Company increased its position in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) by 775.6% in the 1st quarter, Holdings Channel reports. The firm owned 154,634 shares of the company’s stock after purchasing an additional 136,973 shares during the period. The Manufacturers Life Insurance Company’s holdings in Alumis were worth $3,407,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. MPM Bioimpact LLC acquired a new position in Alumis in the 4th quarter valued at $23,443,000. Orbimed Advisors LLC acquired a new stake in Alumis during the 2nd quarter worth $5,779,000. Woodline Partners LP grew its holdings in shares of Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after buying an additional 1,558,660 shares in the last quarter. Samsara Biocapital LLC raised its position in shares of Alumis by 47.0% in the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the last quarter. Finally, Cormorant Asset Management LP raised its position in shares of Alumis by 69.3% in the fourth quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after buying an additional 1,488,200 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Citigroup restated a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Morgan Stanley restated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.30.

Read Our Latest Stock Analysis on ALMS

Insiders Place Their Bets

In other news, insider David M. Goldstein sold 2,596 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $68,456.52. Following the transaction, the insider owned 30,970 shares of the company’s stock, valued at $816,678.90. This represents a 7.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sanam Pangali sold 5,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider owned 11,111 shares of the company’s stock, valued at approximately $311,108. This represents a 31.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 19,953 shares of company stock worth $534,311. Corporate insiders own 33.70% of the company’s stock.

Alumis Price Performance

Alumis stock opened at $27.60 on Friday. The firm has a 50 day simple moving average of $25.62 and a 200-day simple moving average of $25.26. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -13.94 and a beta of -0.69. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35.

Alumis (NASDAQ:ALMS – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. Equities analysts expect that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.

Alumis Company Profile

(Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.